RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q2 FY23 results · Jul–Sep 2022
RPG Life Sciences reported revenue from operations of ₹134.79 crore (up 19.7% from Q2 FY22) and net profit of ₹19.97 crore (up 26.8% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a standalone basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 134.79 | 112.65 | +19.7% | 128.93 | +4.5% |
| Other income | 1.23 | 0.71 | +73.2% | 1.22 | +0.8% |
| Total income | 136.02 | 113.36 | +20.0% | 130.15 | +4.5% |
| Profit before tax | 27.01 | 22.35 | +20.9% | 25.12 | +7.5% |
| Net profit for the period | 19.97 | 15.75 | +26.8% | 18.21 | +9.7% |
| EPS, basic (₹) | 12.08 | 9.52 | +26.9% | 11.01 | +9.7% |
| Net margin (%) | 14.8 | 14.0 | 14.1 |
Standalone
- Filed with BSE
- 19 Oct 2022, 15:43 IST
- Board meeting
- 17 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE